Open Label trial to assess Iressa in prostate cancer patients
Study identifier:1839US/0040
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Phase II, Open-label trial to assess the activity of ZD1839 (IRESSA TM) in patients with recurrent prostate cancer who have rising serum PSA levels despite serum testosterone < 50mg/dl
Medical condition
prostate cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
Gefitinib
Sex
All
Actual Enrollment
100
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 May 2001
Primary Completion Date: -
Study Completion Date: 01 Feb 2003
Study design
Allocation: N/A
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: None
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
